HomeAI · summaries
Storia in 4 fonti
Lilly, Hanmi sign $1.26bn licensing deal for sonefpeglutide
Eli Lilly and Company has entered into a licensing agreement worth up to $1.26bn with Hanmi Pharm to develop, manufacture and commercialise Hanmi’s biologic drug candidate, sonefpeglutide, worldwide excluding Korea.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
adnkronos.com
Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog)
Lilly licenses Hanmi's sonefpeglutide(LAPSGLP-2 analog) for multiple indications
- ·
koreaherald.com
Hanmi inks $1.26b licensing deal with Eli Lilly
Hanmi Pharmaceutical said Monday it has clinched an outlicensing contract with Eli Lilly for sonefpeglutide, its long-acting glucagon-like peptide 2, or GLP-2,
- ·
pharmaceutical-technology.com
Lilly, Hanmi sign $1.26bn licensing deal for sonefpeglutide
Eli Lilly and Company has entered into a licensing agreement worth up to $1.26bn with Hanmi Pharm to develop, manufacture and commercialise Hanmi’s biologic drug candidate,…
- ·
benzinga.com
Eli Lilly Deepens Innovation Push Through New Biopharma Collaborations - Eli Lilly (NYSE:LLY)
Eli Lilly signs drug development deals with Hanmi and Haisco as Retevmo Phase 3 data show an 83% cut in recurrence risk.